Cargando…

Piperacillin-Tazobactam (TZP) Resistance in Escherichia coli Due to Hyperproduction of TEM-1 β-Lactamase Mediated by the Promoter Pa/Pb

TEM-1, mediated by plasmid and transposon, is the most commonly encountered β-lactamase in Gram-negative bacteria. Four different promoters upstream of bla(TEM)-related genes have been identified: the weak P3 promoter, and the strong promoters Pa/Pb, P4, and P5. In this study, we investigated the ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Kaixin, Tao, Ying, Han, Lizhong, Ni, Yuxing, Sun, Jingyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476967/ https://www.ncbi.nlm.nih.gov/pubmed/31040841 http://dx.doi.org/10.3389/fmicb.2019.00833

Ejemplares similares

Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla(TEM-1B)
por: Hubbard, Alasdair T. M., et al.
Publicado: (2020)

1809. Treatment Outcomes in Piperacillin-tazobactam Non-susceptible (TZP-NS)/Ceftriaxone Susceptible (CRO-S) Infections
por: Dubrovskaya, Yanina, et al.
Publicado: (2022)

2407. Emerging Piperacillin/Tazobactam Resistance in Escherichia coli and Klebsiella sp.
por: Suseno, Mira, et al.
Publicado: (2018)

Rapid Detection of Piperacillin-Tazobactam Resistance in Klebsiella pneumoniae and Escherichia coli
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

Detection of Escherichia coli and Associated β-Lactamases Genes from Diabetic Foot Ulcers by Multiplex PCR and Molecular Modeling and Docking of SHV-1, TEM-1, and OXA-1 β-Lactamases with Clindamycin and Piperacillin-Tazobactam
por: Shahi, Shailesh K., et al.
Publicado: (2013)

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli
por: Schechter, Lisa M., et al.
Publicado: (2018)

Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli
por: Rodríguez-Villodres, Ángel, et al.
Publicado: (2021)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort
por: Thønnings, Sara, et al.
Publicado: (2019)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Minimal impact of selective susceptibility reporting on the use of piperacillin-tazobactam for Escherichia coli and Klebsiella bacteremia
por: Zahlanie, Yorgo, et al.
Publicado: (2021)

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test
por: Rodríguez Villodres, Angel, et al.
Publicado: (2022)

Hyperproduction of poly(4-hydroxybutyrate) from glucose by recombinant Escherichia coli
por: Zhou, Xiao-Yun, et al.
Publicado: (2012)

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli
por: Seo, Yu Bin, et al.
Publicado: (2017)

1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
por: Aslan, Abdullah Tarik, et al.
Publicado: (2018)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible
por: Baker, Thomas M, et al.
Publicado: (2018)

1061. Decreased Utilization of Piperacillin–Tazobactam for Escherichia coli and Klebsiella Bacteremia due to Selective Susceptibility Reporting
por: Zahlanie, Yorgo, et al.
Publicado: (2019)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

646. Adapting the modified Carbapenem Inactivation Method to assess for possible beta-lactamase mediated resistance in Piperacillin-Tazobactam resistant/ Ceftriaxone susceptible Escherichia. coli and Klebsiella pneumoniae
por: Lawandi, Alexander, et al.
Publicado: (2020)

Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: A retrospective study
por: Meybeck, Agnès, et al.
Publicado: (2008)

305. Prevalence of Ceftriaxone Susceptible, Piperacillin-tazobactam Non-susceptible Escherichia coli Bacteremia in Patients with Hematologic Malignancy
por: Spitznogle, Sarah L, et al.
Publicado: (2020)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model
por: Islam, Kamrul, et al.
Publicado: (2022)

2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia
por: Tran, Kieu-Nhi, et al.
Publicado: (2019)

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)

486 Meropenem and Piperacillin-tazobactam have Comparable Outcomes in Treatment of Bloodstream Infections Caused by Extended Spectrum Beta-lactamase Producing E.coli and Klebsiellae
por: Harris, Patrick, et al.
Publicado: (2014)

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007–18)
por: Walkty, A., et al.
Publicado: (2022)

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
por: Felton, T W, et al.
Publicado: (2014)

Tazobactam and piperacillin-induced thrombocytopenia: A case report
por: CHEN, HONG, et al.
Publicado: (2016)

Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
por: Kyriakou, Aikaterini, et al.
Publicado: (2019)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
por: Workum, J D, et al.
Publicado: (2020)

Piperacillin/tazobactam/vancomycin: Cast nephropathy: case report
Publicado: (2022)

Piperacillin/tazobactam: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy
por: Wong, Jane CY, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hgh3e443dg2ed30s06egtsk371